Title: Clinical observation of methylprednisolone sodium succinate for injection combined with ganciclovir in the treatment of severe viral meningitis
Abstract: Objective
To investigate the value of methylprednisolone sodium succinate for injection combined with ganciclovir in the treatment of severe viral meningitis.
Methods
Ninety-eight patients with severe viral meningitis from January 2016 to February 2018 were enrolled in Shanxi Coal Central Hospital. The patients were divided into observation group and control group according to the random number table method, with 49 cases in each group. On the basis of routine treatment, the control group was treated with ganciclovir + dexamethasone, while the observation group was treated with ganciclovir + methylprednisolone sodium succinate for injection. The clinical efficacy, symptoms and signs, serum inflammatory factors [procalcitonin (PCT), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-8 (IL-8)] levels and functional scores [neurological function (NIHSS score), motor function (Fugl-Meyer score), activity of life (ADL score) changes before and after treatment were compared between the two groups. The incidences of adverse reactions during treatment were compared between the two groups.
Results
①Clinical efficacy: the total effective rate of observation group was 91.84% (45/49), which was higher than that of control group [75.51% (37/49), P 0.05).
Conclusions
The effect of methylprednisolone sodium succinate for injection combined with ganciclovir on severe viral meningitis is remarkable, which is beneficial to alleviating clinical symptoms and signs, reducing the degree of inflammation reaction, improving the functional status of patients, with certain safety.
Key words:
Severe viral meningitis; Ganciclovir; Methylprednisolone sodium succinate for injection; Inflammatory factors; Neurological function
Publication Year: 2019
Publication Date: 2019-03-25
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot